Verwandte Artikel zu Novel and Innovative Drug Delivery Systems to Overcome...

Novel and Innovative Drug Delivery Systems to Overcome Chemoresistance in Human Malignancies (Novel approaches to overcome cancer resistance to conventional therapies) - Softcover

 
9780443457173: Novel and Innovative Drug Delivery Systems to Overcome Chemoresistance in Human Malignancies (Novel approaches to overcome cancer resistance to conventional therapies)
Softcover
ISBN 10: 0443457174 ISBN 13: 9780443457173
Verlag: Academic Press, 2026

Inhaltsangabe

Novel and Innovative Drug Delivery Systems to Overcome Chemoresistance in Human Malignancies addresses the critical challenge of cancer chemoresistance, synthesizing insights from cancer biology, molecular biology, biotechnology, and nanotechnology. The book explores the complex mechanisms underlying drug resistance, including alterations in key signaling pathways and the tumor microenvironment's role in cancer cell survival. It highlights advancements in drug delivery technologies, such as nanomedicine and biomimetic strategies, which enhance drug targeting and minimize off-target effects. The integration of techniques like CRISPR-Cas9 and artificial intelligence in developing next-generation therapies is also emphasized.

For an academic audience, this book serves as an essential resource to foster interdisciplinary collaboration in cancer research. It equips researchers, clinicians, and industry professionals with the knowledge needed to navigate the evolving landscape of cancer therapeutics, addressing critical challenges in drug delivery and chemoresistance to improve patient outcomes.

Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.

Über die Autorinnen und Autoren

Dr. Shuvomoy Banerjee is an accomplished academic and researcher with extensive experience as an editorial board member for several reputable journals, including Reviews in Medical Virology, and as an associate editor for the IAR University Journal. He holds a Ph.D. in cancer biology from Bose Institute, Kolkata, and has post-doctoral research experience at the University of Pennsylvania and Beckman Research Institute. Currently an Assistant Professor at the Institute of Advanced Research, Gandhinagar, Dr. Banerjee specializes in cancer immunology and tumor virology. His prolific contributions include numerous publications in high-impact journals. He has led multiple extramural research projects funded by organizations such as the Science and Engineering Research Board (SERB) and the Gujarat State Biotechnology Mission. His active participation in various scientific organizations underscores his credibility and thought leadership in the field of cancer research.

Regenerate response

Dr. Dhiraj Bhatia, an associate professor at IIT-Gandhinagar, specializes in DNA nanotechnology, chemical biology, and drug delivery systems. With a Ph.D. from NCBS-TIFR and postdoctoral work including an HFSP fellowship at Institut Curie, he has pioneered research in structural DNA nanotechnology for biomedical applications. His publications in high-impact journals like ACS Nano, Nature Nanotechnology, and Angewandte Chemie showcase his expertise. His work on programmable DNA nanodevices, hydrogels, and targeted drug delivery addresses critical challenges such as cancer chemoresistance. Recognized with awards like the Merck Young Scientist Award and INYAS-INSA Membership, Dr. Bhatia is also an experienced reviewer and mentor, actively organizing interdisciplinary conferences

Von der hinteren Coverseite

Novel and Innovative Drug Delivery Systems to Overcome Chemoresistance in Human Malignancies addresses the critical challenge of cancer chemoresistance, synthesizing insights from cancer biology, molecular biology, biotechnology, and nanotechnology. This book explores the complex mechanisms underlying drug resistance, including alterations in key signaling pathways and the tumor microenvironment's role in cancer cell survival. It highlights advancements in drug delivery technologies, such as nanomedicine and biomimetic strategies, which enhance drug targeting and minimize off-target effects. The integration of techniques like CRISPR-Cas9 and artificial intelligence in developing next-generation therapies is also emphasized.

For an academic audience, this book serves as an essential resource to foster interdisciplinary collaboration in cancer research. It equips researchers, clinicians, and industry professionals with the knowledge needed to navigate the evolving landscape of cancer therapeutics, addressing critical challenges in drug delivery and chemoresistance to improve patient outcomes.

„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.

Verlag
Academic Press
Erscheinungsdatum
2026
Sprache
Englisch
ISBN 10 
0443457174
ISBN 13 
9780443457173
Einband
Taschenbuch
Anzahl der Seiten
458
Herausgeber
Banerjee
Kontakt zum Hersteller
Elsevier Health Science
tradeorders@elsevier.com

London Wall 125
London
EC2Y 5AS
Vereinigtes Königreich
Verantwortliche Person
eVatmaster Consulting GmbH
497000000000
contact@evatmaster.com

Bettinastr. 30,60325
Frankfurt am Main
60325
Deutschland